Showing results (71-80 of 76) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
The Lancet. Infectious Diseases|April 13, 2024
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trialHong-Xing Pan, Ling-Xian Qiu, Qi Liang, et al.Science Bulletin|September 24, 2023
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trialYue-Mei Hu, Zhao-Feng Bi, Ya Zheng, et al.The Lancet. Infectious Diseases|June 30, 2026
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trialHong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, et al.The Lancet. Infectious Diseases|August 29, 2022
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trialFang-Hui Zhao, Ting Wu, Yue-Mei Hu, et al.JAMA|August 8, 2020
Determination of Brain Death/Death by Neurologic Criteria: The World Brain Death ProjectDavid M Greer, Sam D Shemie, Ariane Lewis, et al.Journal of the National Cancer Institute|May 16, 2019
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical TrialYou-Lin Qiao, Ting Wu, Rong-Cheng Li, et al.Pageof 8